Category: Uncategorized

Immunome Appoints Purnanand Sarma, PhD, as President and Chief Executive Officer

Industry Veteran to Take the Helm of Next-Generation Oncology Company Focused on Harnessing Human Immune Response

Exton, PA, June 24, 2019 – Immunome, a biotechnology company focused on discovering  first-in-class therapeutics by leveraging the most highly educated components of the human immune system from cancer patients, announced today that industry veteran Purnanand Sarma, PhD, has joined Immunome as President and Chief Executive Officer. Sarma brings more than 25 years of industry experience with a proven track record in drug development, fund raising, and growing companies across multiple R&D platforms ranging from venture-backed biotechnology start-ups to large-cap pharmaceutical companies. Immunome’s former Chief Executive Officer, Michael Morin, PhD, assumes the role of Chief Scientific Officer, allowing him to focus his time and expertise on maximizing the value of the company’s proprietary breakthrough R&D engine.

“Immunome is poised to emerge as a dominant player in developing next-generation therapies for cancer, offering tremendous potential for new treatments and hope to patients and their families,” said Sarma. “Immunome’s unique ability to harness the information from the most educated human B cells, coupled with its breakthrough target interrogation techniques, delivers a truly powerful discovery engine, and I am very excited to join the team and create what could be a revolution in oncology drug discovery. I am grateful to the exceptional leadership of Mike Morin, producing incredible scientific advances that have rapidly accelerated our discovery engine, which now delivers multiple novel and exciting targets on a monthly basis.”  

“Sarma is a seasoned biotech executive with an impressive track record in scaling up promising companies,” said Morin. “We are thrilled to have him lead our team as we begin to unveil our differentiated approach to immunology, share the recent success and advancements of our innovative discovery platform, build out a development pipeline and articulate our vision for a fully integrated company.”

Prior to joining Immunome, Sarma was the President & CEO of Taris Biomedical, which he built during the last nine years into a leader in therapeutic urology focused on diseases such as bladder cancer and overactive bladder. In addition to raising more than $100 million in equity capital, Sarma also sold one of Taris’ products to Allergan (NYSE:AGN) in a transaction worth up to $587 million. Prior to TARIS, he served in several leadership roles at Cephalon Corporation, which was acquired by Teva Pharmaceutical Industries (NYSE:TEVA); Nektar Therapeutics (NASDAQ:NKTR); and SmithKline Beecham, now Glaxo SmithKline (NYSE:GSK).  Sarma earned his PhD in Pharmaceutics from the University of Minnesota and B. Pharm from Andhra University, Visakhapatnam, India. Sarma also serves as an independent Board Member at Ohm Oncology and Vaxess Technologies Inc.

About Immunome
Immunome is a biotechnology company focused on leveraging the human immune system to change the paradigm of cancer treatment. Immunome’s growing pipeline of cancer immunotherapies, targeting novel areas of cancer biology, is fueled by a proprietary, outcome-based discovery engine that was originally developed at Massachusetts Institute of Technology’s Whitehead Institute. Our technology both captures and deeply interrogates patient immune responses to uncover novel tumor antigens and fully human antibodies with therapeutic potential against those targets. For more information about the company, visit  http://immunome.com.

Investor Contact
Purnanand Sarma
President and CEO
Immunome, Inc.
investors@immunome.com

Media Contact
Jennifer Guinan
Sage Strategic Marketing
610.410.8111
Jennifer@sagestrat.com

Immunome Raises $12.2 Million in Additional Series A Financing

Funding allows further development of novel, outcome-based cancer immunotherapy discovery engine

October 6, 2016, Philadelphia, PA – Immunome, Inc., a biotechnology company focused on developing transformative immunotherapies to treat cancer, today announced it has closed on an aggregate of $10.2 million in 2016 Series A Preferred Stock investments. An additional $2 million is committed to be funded by June 30, 2017.  The Company plans to use the proceeds to further develop and scale up Immunome’s discovery engine and pipeline of cancer therapeutics.

“We thank all of our investors for their confidence and enthusiastic support of the development and scale up of our technology and novel cancer immunotherapy candidates,” said Jane H. Hollingsworth, Immunome’s chief executive officer. “We believe that this support has enhanced our ability to maximize the value of our unique immunotherapy approach.”

Michael J. Morin, PhD, Immunome’s president and chief scientific officer commented, “This funding allows us to continue to aggressively optimize and implement our unique outcome-based discovery engine.  We begin the process with patients who have cancer-educated immune systems, particularly those who have had a robust response to a checkpoint inhibitor. Our platform then generates large libraries of hybridomas, utilizes high-content screening approaches and identifies targets of the most important antibodies, before finally engineering drug-like qualities into the therapeutic candidates.”

About Immunome
Immunome is a biotechnology company with a unique and powerful outcome-based immunotherapy discovery engine. Originally developed at Massachusetts Institute of Technology’s Whitehead Institute, Immunome’s platform leverages the patient immunological response to circumvent the weaknesses, complications and inefficiencies of traditional discovery research. Immunome focuses on the simultaneous discovery of novel antigens expressed in patient tumor cells and the cognate native patient antibodies that target those antigens. These antigen-antibody pairs form the basis of the Immunome library and therapeutic pipeline. For more information about the company, visit http://immunome.com.

Investor Contact
Jane H. Hollingsworth
Chief Executive Officer
Immunome, Inc.
investors@immunome.com

Media Contact
Jennifer Guinan
Sage Strategic Marketing
610.410.8111
jennifer@sagestrat.com

Forward-Looking Statements
Certain statements in this press release concerning the financing, the development of Immunome’s products and the potential benefits and attributes of these products are “forward-looking statements”, as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release.  Immunome undertakes no obligation to update any forward-looking statements for any reason.

 

Immunome Raises $5 Million Series A Financing to Advance Novel Cancer Immunotherapies

$5 million funded to advance Immunome’s native human cancer antibody platform

April 20, 2016, Philadelphia, PA – Immunome, Inc., a biotechnology company focused on developing transformative immunotherapies to treat cancer, today announced it has raised $5 million in Series A Preferred Stock financing. The company anticipates using the proceeds to fund further development of Immunome’s growing pipeline of cancer therapeutic antibodies. The financing included investments from new and existing Immunome investors.

Jane Hollingsworth, Immunome CEO, said, “We thank all of our investors for their confidence and continued support of the development of our technology and pipeline of novel cancer immunotherapy candidates. Our exceptionally productive discovery engine  identifies native antibodies and their target antigens raised during a cancer patient’s humoral response. We believe that Immunome is poised to meet the demand for less toxic, novel and highly selective cancer antibodies for the next-generation of immuno-oncology therapies, a market expected to grow to $35 billion by 2025.”

Scott Dessain, MD, PhD, Immunome co-founder and Chief Scientific Officer, commented, “Immunome has the potential to identify novel antigen antibody pairs from all cancer types and patient subsets, including those that have responded to checkpoint inhibitors. We anticipate identifying multiple therapeutic candidates for T-cell activating and ADC therapies.”

Broadband Capital Management acted as exclusive placement agent for the financing.

About Immunome
Immunome is a biotechnology company with a unique and powerful immunotherapy discovery engine. Immunome’s proprietary RealMAb™ technology enables the simultaneous discovery of novel antigens and the cognate native human antibodies that target those antigens. RealMAb, originally developed at Massachusetts Institute of Technology’s Whitehead Institute, utilizes the human immune system response to circumvent the weaknesses, complications and inefficiencies of non-human approaches. After identification, Immunome employs its proprietary screening technology to screen for functional and specific cancer activity of these antigen antibody pairs. For more information about the company, visit http://immunome.com.

Investor Contact
Jane H. Hollingsworth
Chief Executive Officer
Immunome, Inc.
investors@immunome.com

Media Contact
Jennifer Guinan
Sage Strategic Marketing
610.410.8111
Jennifer@sagestrat.com

Forward-Looking Statements
Certain statements in this press release concerning the development of Immunome’s products and the potential benefits and attributes of these products are “forward-looking statements”, as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release.  Immunome undertakes no obligation to update any forward-looking statements for any reason.

Immunome Appoints Michael J. Morin, PhD, as President and Chief Scientific Officer

Former Pfizer Research Executive to Lead Development of Novel Cancer Therapeutics Leveraging Tumor Immunology

Philadelphia, PA, March 8, 2016 – Immunome, a biotechnology company leveraging tumor immunology to develop cancer therapeutics, today announced that industry veteran Michael J. Morin, PhD, has joined Immunome as president and chief scientific officer. Dr. Morin offers more than 25 years in pharmaceutical research and development with a proven track record of developing approvable cancer therapy candidates.

“Immunome is on the leading edge of the immunotherapy revolution, developing breakthrough products to treat cancer,” said Jane H. Hollingsworth, executive chair and interim chief executive officer of Immunome. “We do this by isolating the antibodies generated by the patients’ own immune response, allowing us to discover, develop and commercialize highly targeted antibodies against novel universal cancer antigens. Mike’s exceptional track record in the discovery and development of cancer treatments allows us to most effectively industrialize and enhance the productivity of our groundbreaking immunotherapy technology.”

Dr. Morin’s oncology career spans academia and industry, including 17 years at Pfizer where he served as vice president of global research and development overseeing immunology, anti-bacterials and cancer drug discovery in Groton, CT. Approximately 40 clinical candidates were discovered under Dr. Morin’s leadership at Pfizer.  Following his time at Pfizer, Dr. Morin worked as an advisor to venture-backed biotechnology and publicly held pharmaceutical companies. Dr. Morin also actively participates in a variety of cancer research organizations, including as long-standing co-chair of the NCI Experimental Therapeutics (NExT) review panel, chair of the Drug Discovery Initiative of the Children’s Tumor Foundation, and as a member of the scientific advisory board of the Ontario Institute of Cancer Research.

“Immunome is well positioned to rapidly advance its exceptional target discovery engine and grow pipeline of cancer therapeutic candidates,” said Dr. Morin. “This is an extraordinary opportunity to harness the power of the human immune response to identify unprecedented targets and antibody therapeutics to treat cancer and other life-threatening diseases.”

Immunome’s founder and former chief scientific officer, Scott Dessain, MD, PhD, assumes the role of chief technology officer allowing him to focus his time and expertise on maximizing and enhancing the value of the company’s novel target discovery and functional screening technology.

About Immunome
Immunome is a biotechnology company leveraging tumor immunology with a unique and powerful immunotherapy discovery engine. Immunome’s proprietary RealMAb™ technology enables the simultaneous discovery of novel antigens and the cognate native human antibodies that target those antigens. RealMAb, originally developed at the Massachusetts Institute of Technology’s Whitehead Institute, utilizes the human immune system response to circumvent the weaknesses, complications and inefficiencies of non-human approaches. After identification, Immunome employs its proprietary screening technology to screen for functional and specific cancer activity of these antigen antibody pairs. For more information about the company, visit http://immunome.com.

Investor Contact
Jane H. Hollingsworth
Interim CEO and Executive Chair
Immunome, Inc.
investors@immunome.com

Media Contact
Jennifer Guinan
Sage Strategic Marketing
610.410.8111
Jennifer@sagestrat.com

Forward-Looking Statements
Certain statements in this press release concerning the development of Immunome’s products and the potential benefits and attributes of these products are “forward-looking statements”, as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release.  Immunome undertakes no obligation to update any forward-looking statements for any reason.